A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Conditions:   Diarrhea;   Diarrhea Infectious Intervention:   Other: no intervention Sponsors:   Centre for Infectious Disease Research in Zambia;   Groupe de Recherche Action en Sante Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2020 Category: Research Source Type: clinical trials

A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in Africa
Conditions:   Diarrhea;   Diarrhea Infectious Intervention:   Other: no intervention Sponsors:   Centre for Infectious Disease Research in Zambia;   European Vaccine Initiative;   Groupe de Recherche Action en Sante Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2020 Category: Research Source Type: clinical trials

Phase 2 Shigella Vaccine and Challenge
Conditions:   Immunisation;   Shigella Infection Interventions:   Other: Placebo;   Biological: Shigella sonnei strain 53G;   Biological: WRSs2 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2020 Category: Research Source Type: clinical trials

A double-blind placebo-controlled trial of azithromycin to reduce mortality and improve growth in high-risk young children with non-bloody diarrhoea in low resource settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol
DiscussionExpanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy impli...
Source: Trials - January 13, 2020 Category: Research Source Type: clinical trials

Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
Condition:   Shigella Interventions:   Biological: SF2a-TT15 Shigella Vaccine;   Other: Placebo;   Biological: S. flexneri 2a strain 2457T Challenge Agent Sponsor:   University of Maryland, Baltimore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 4, 2019 Category: Research Source Type: clinical trials

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
Condition:   Shigellosis Interventions:   Biological: Shigella 4V;   Biological: MenACWY;   Biological: Rabies;   Biological: Diphtheria, Tetanus and Pertussis (DTaP);   Biological: Placebo Sponsors:   LimmaTech Biologics AG;   Kenya Medical Research Institute;   KEMRI-Wellcome Trust Collaborative Research Program Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2019 Category: Research Source Type: clinical trials

Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
Conditions:   Dysentery, Shigella;   Shigellosis;   Diarrhea Interventions:   Drug: Ciprofloxacin;   Drug: Azithromycin Sponsors:   Oxford University Clinical Research Unit, Vietnam;   Children's Hospital Number 2, Ho Chi Minh City, Vietnam;   University of Liverpool Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2019 Category: Research Source Type: clinical trials